Baseline characteristics and demographics of infliximab-treated and etanercept-treated patients with SpA and reason for discontinuation
| Infliximab n=1319 | Etanercept n=1015 | |||
| INF (n=320) | CT-P13 (n=999) | ETN (n=493) | SB4 (n=522) | |
| Age (years) | 42 (14) | 42 (13) | 41 (14) | 41 (14) |
| Disease duration (years) | 13 (12) | 10 (11) | 12 (12) | 11 (12) |
| Sex, men, n (%) | 183 (57) | 576 (58) | 235 (48) | 261 (50) |
| AS, n (%) | 183 (57) | 461 (46) | 204 (41) | 199 (38) |
| nraxSpA or uSpA, n (%) | 137 (43) | 538 (54) | 289 (59) | 323 (62) |
| Psoriasis (%)* | 6 | 3 | 7 | 5 |
| Inflammatory bowel disease (%)* | 10 | 11 | 2 | 2 |
| CRP (mg/L) | 15 (21) | 13 (22) | 11 (18) | 10 (15) |
| Patient global (mm) | 59 (24) | 64 (24) | 57 (22) | 59 (23) |
| Patient pain (mm) | 62 (23) | 59 (24) | 59 (24) | 59 (22) |
| ASDAS | 3.4 (1.0) | 3.4 (1.0) | 3.1 (0.9) | 3.0 (0.9) |
| BASDAI (mm) | 6.0 (2.0) | 5.6 (2.0) | 5.4 (2.0) | 5.4 (1.9) |
| BASFI (mm) | 4.4 (2.5) | 4.8 (2.4) | 4.1 (2.4) | 4.1 (2.5) |
| Concomitant csDMARD, n (%) | 96 (44) | 238 (31) | 98 (29) | 85 (22) |
| Country | ||||
| Iceland, n (%) | 5 (2) | 70 (7) | 8 (2) | 0 (0) |
| Norway, n (%) | 2 (1) | 104 (10) | 7 (1) | 20 (4) |
| Finland, n (%) | 21 (7) | 38 (4) | 94 (19) | 0 (0) |
| Denmark, n (%) | 19 (6) | 546 (55) | 19 (4) | 79 (15) |
| Sweden, n (%) | 273 (85) | 241 (24) | 365 (74) | 423 (81) |
| Reason for discontinuation | ||||
| Adverse event, n (%) | 48 (15) | 131 (13) | 33 (7) | 22 (4) |
| Death, n (%) | 1 (0) | 0 (0) | 0 (0) | 1 (0) |
| Inefficacy, n (%) | 61 (19) | 139 (14) | 91 (19) | 45 (9) |
| Pregnancy, n (%) | 3 (1) | 4 (0) | 5 (1) | 0 (0) |
| Remission, n (%) | 1 (0) | 0 (0) | 1 (0) | 0 (0) |
| Non-medical switch, n (%) | 46 (14) | 23 (2) | 81 (16) | 1 (0) |
| Other, n (%) | 51 (16) | 70 (7) | 64 (13) | 22 (4) |
Numbers are means (SD) unless otherwise stated.
*Comorbidities available from Sweden, Denmark and Finland.
AS, ankylosing spondylitis; ASDAS, Ankylosing Spondylitis Disease Activity Score; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index;BASFI, Bath Ankylosing Spondylitis Function Index; CRP, C reactive protein; csDMARD, conventional synthetic disease-modifying antirheumatic drug; CT-P13, infliximab biosimilar; ETN, etanercept originator; INF, infliximab originator; nraxSpA, non-radiographical axial spondyloarthritis; SB4, etanercept biosimilar; SpA, spondyloarthritis; uSpA, undifferentiated spondyloarthritis.